Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model

Neurourology and Urodynamics

Volumn 17, Issue 6, 1998, Pages 599-611

  Kobelt, Gisela ^a   Jönsson, Linus ^b   Mattiasson, Anders ^c  

^a Health Dynamics International   (United Kingdom)

^b STOCKHOLM HEALTH ECONOMICS   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost effectiveness; Cost utility; Modeling; Overactive bladder; Tolterodine

Indexed keywords

TOLTERODINE;

ARTICLE; BLADDER DYSFUNCTION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; PATIENT SATISFACTION; QUALITY OF LIFE;

BENZHYDRYL COMPOUNDS; COHORT STUDIES; COST-BENEFIT ANALYSIS; CRESOLS; DRUG COSTS; HUMANS; MARKOV CHAINS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; SENSITIVITY AND SPECIFICITY; URINARY BLADDER DISEASES;

EID: 0031771662     PISSN: 07332467     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6777(1998)17:6<599::AID-NAU4>3.0.CO;2-J     Document Type: Article

References (23)

1. Abrams P, Freeman, Anderstroem, Mattiasson A (1998): Tolterodine, a new antimuscarinic agent, as effective but better tolerated than oxybutynin in patients with detrusor instability. Br J Urol 81:801-810.
2. Appell RA (1997): Clinical efficacy and safety of tolterodine in the treatment of overactive bladder. A pooled analysis. Urology 50(Suppl 6A):90-96.
3. Bloom B, Buxton M, Drummond M, Luce B, Sheldon T (1996): In: Towse A (ed): "The Pros and Cons of Modelling in Economic Evaluation." International Society for Technology Assessment in Health Care. London: Office of Health Economics.
4. Drummond MF, O'Brien B, Stoddard GL, Torrance GW (1997): "Methods for Economic Evaluation of Health Care Programmes," 2nd ed. New York: Oxford University Press.
5. The EuroQol Group (1990): EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 16:199-208.
6. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996): "Cost-effectiveness in Health and Medicine." New York: Oxford University Press.
7. Herzog AR, Diokno AC, Fultz NH (1989): Urinary incontinence: Medical and psychosocial aspects. Rev Gerontol Geriatr 9:74-119.
8. Hunskaar S, Visnes A (1991): The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc 39:378-382.
9. Johannesson M (1996). "Theory and Methods of Economic Evaluation in Health Care." Boston: Kluwer Academic Publishers.
10. Johannesson M, O'Connor RM, Kobelt-Nguyen G, Mattiasson A (1997): Willingness to pay for reduced incontinence symptoms. Br J Urol 80:557-562.
11. Kobelt G (1996): "Health Economics: A Guide to Economic Evaluation." London: Office of Health Economics.
12. Kobelt G, Mattiasson A, Abrams P (1997): Correlations between symptoms of overactive bladder and quality of life (Abstract). Neurourol Urodynam 16:165-166.
13. Kobelt G (1997): Economic considerations and outcome measurement in urge incontinence. Urology 50(Suppl 6A): 100-107.
14. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997): A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988-993.
15. Lenderking WR, Nackley JF, Anderson RB, Testa MA (1996): A review of the quality of life aspects of urinary urge incontinence. Pharmacoeconomics 9:11-23.
16. Mason JM (1994): Cost-per QALY league tables: Their roles in pharmacoeconomic analysis. Pharmacoeconomics 5(6):472-481.
17. Rittenhouse B (1996): "Uses of Models in Economic Evaluations of Medicines and Other Health Technologies." London: Office of Health Economics.
18. Salvatore S, Khullar V, Cardozo L, Kelleher D, Abbott D, Hill S (1995): Long term outcome of women with detrusor instability treated with oxybutynin (Abstract). Neurourol Urodynam 14:460-462.
19. Sonnenberg PA, Beck JR (1993): Markov models in medical decision making: Practical guide. Med Decis Making 13:322-328.
20. Stewart AL, Hays RD, Ware JE (1988): The MOS short-form general health survey: Reliability and validity in a patient population. Med Care 26:724-735.
21. Williams A (1995): "The Measurement and Valuation of Health: A Chronicle" (discussion paper 136). York, United Kingdom: University of York.
22. Wyman JF, Harkins SW, Fantl A (1990): Psychosocial impact of urinary incontinence in the community dwelling population. J Am Geriatr Soc 38:282-288.
23. Wyman JP (1994): The psychiatric and emotional impact of female pelvic floor dysfunction. Curr Opin Obstet Gynecol 6(4):336-339.